L’anticorps Souris Monoclonal anti-Ret Proto-Oncogene a été validé pour ELISA. Il convient pour détecter Ret Proto-Oncogene dans des échantillons de Humain. Il y a 2+ publications disponibles.
RET
Reactivité: Humain
WB, IHC, IF, FACS, IC, LCI
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
ELISA: 1/10000
Restrictions
For Research Use only
Format
Liquid
Buffer
Ascitic fluid containing 0.03 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C,-20 °C
Stockage commentaire
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Young, Anderson, Anderson: "Guidance cues involved in the development of the peripheral autonomic nervous system." dans: Autonomic neuroscience : basic & clinical, Vol. 112, Issue 1-2, pp. 1-14, (2004) (PubMed).
Myers, Mulligan: "The RET receptor is linked to stress response pathways." dans: Cancer research, Vol. 64, Issue 13, pp. 4453-63, (2004) (PubMed).
Antigène
Ret Proto-Oncogene (RET)
Autre désignation
RET
Sujet
RET (ret proto-oncogene) is a member of the cadherin superfamily and a receptor tyrosine kinase, which are cell-surface molecules that transduce signals for cell growth and differentiation. It can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Ligands that bind the Ret receptor include the glial cell line-derived neurotropic factor (GDNF) and its congeners neurturin, persephin and artemin. Alterations in the corresponding Ret gene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma and a congenital developmental disorder known as Hirschsprung